Corvus Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Soquelitinib demonstrated rapid, deep, and durable clinical responses in moderate to severe atopic dermatitis, with a clean safety profile and no rebound after treatment. Mechanistic data show selective immune modulation and increased Tregs, supporting potential disease modification and broad applicability.
-
Soquelitinib, a selective oral ITK inhibitor, demonstrated strong efficacy and durable responses in atopic dermatitis, including in patients resistant to prior therapies, with a favorable safety profile. Large market opportunities exist, and multiple phase II and III trials are planned through 2026.
-
Phase I results for Soquelitinib in atopic dermatitis show strong efficacy, durable responses, and a favorable safety profile, including in patients with prior systemic therapy. The drug’s novel mechanism induces Tregs and reduces key cytokines, supporting broad potential in immune diseases. Phase II trials in AD, asthma, and HS are planned.
Fiscal Year 2025
-
Soquelitinib showed strong efficacy and durable responses in atopic dermatitis and PTCL, with robust safety and broad applicability. Financial position is solid after a $200M financing, supporting an expanded clinical pipeline and cash runway into 2028.
-
Soquelitinib is advancing in both oncology and atopic dermatitis, with strong early safety and efficacy data and a pivotal phase II AD trial set to begin. The program is differentiated by its oral administration and biomarker-driven approach, with significant commercial potential and a solid cash runway.
-
Soquelitinib advanced in atopic dermatitis and T-cell lymphoma, with strong phase I data and phase II trial set for early 2026. Cash reserves support operations into late 2026, and expansion into new indications and potential partnerships are planned.
-
Socolitinib showed strong efficacy and safety in atopic dermatitis, with a phase II trial set to start by year-end and results expected in about 18 months. Cash position improved to $74.4 million, funding operations into Q4 2026, while multiple clinical programs advance on schedule.
-
Soquelitinib, a highly selective ITK inhibitor, demonstrated strong efficacy and safety in phase one atopic dermatitis trials and is advancing in phase three for lymphoma. The drug targets multiple cytokines, offering broad potential in immune and oncology markets, with key extension data expected in Q4.
-
Soquelitinib phase I data in atopic dermatitis showed strong efficacy and safety, with cohort three achieving a 71.1% mean EASI reduction and 63% EASI 75 at day 28. Financially, warrant exercises added $31.3M, extending cash runway into late 2026.
-
Soquelitinib, a selective ITK inhibitor, is showing promising efficacy and safety in phase III lymphoma and phase I atopic dermatitis trials, with durable responses and a favorable safety profile. Expansion into additional autoimmune and solid tumor indications is planned this year.
-
Soquelitinib, a selective ITK inhibitor, is advancing in phase III for PTCL and phase I for atopic dermatitis, showing promising efficacy and safety. The program targets significant unmet needs in oncology and immunology, with broad future potential and key data readouts expected in 2025.
-
Soquelitinib, a highly specific ITK inhibitor, is advancing through phase III trials in T-cell lymphoma and phase I in atopic dermatitis, showing strong efficacy and safety. The drug’s unique mechanism enables broad potential in oncology, autoimmune, and fibrotic diseases.
Fiscal Year 2024
-
Q4 and full year 2024 saw increased R&D spending and net loss, driven by soquelitinib clinical progress and non-cash warrant and partner losses. Soquelitinib showed strong efficacy and safety in lymphoma and atopic dermatitis, with multiple clinical milestones and a solid cash runway into 2026.
-
Phase I interim results for soquelitinib in atopic dermatitis show strong safety and efficacy, with rapid and durable responses comparable to leading biologics. The oral ITK inhibitor blocks multiple cytokines and may offer a novel, convenient alternative for patients seeking non-injectable options.
-
Lead program soquelitinib advanced in both oncology and immunology, with phase III PTCL and phase I atopic dermatitis trials progressing and key data readouts expected in late 2024 and early 2025. Cash runway extends into 2026, supported by recent warrant exercises.
-
The conference highlighted a novel ITK inhibitor platform with lead drug soquelitinib, now in phase III trials for relapsed T-cell lymphoma and phase I for atopic dermatitis. Early data show strong efficacy, safety, and broad potential in cancer and immune diseases.
-
Q2 2024 saw strong progress in ITK inhibitor programs, with soquelitinib showing promising efficacy in PTCL and atopic dermatitis. Cash reserves increased to $47.3M, supporting key clinical milestones into late 2025.
-
Soquelitinib, an oral ITK inhibitor, is advancing to phase III for T-cell lymphoma, showing strong efficacy and safety, with expansion into atopic dermatitis and other immune diseases underway. Recent financing supports operations into 2026, and broad patent protection is in place.